Curr Hematol Malig Rep (2012) 7:133–143 21. Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994;79:143–56. 22. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lympho- blastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–4. 23. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112:3847–55. 24. Cazzaniga G, van Delft FW, Lo Nigro L, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+acute lymphoblastic leukemia. Blood. 2011;118:5559–64. 25. Tonnelle C, Dijon M, Moreau T, et al. Stage specific over- expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation. Mol Immunol. 2009;46:1736–43. 26. Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR- ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia. 2010;24:1200–4. 27. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 dele- tions predict relapse in uniformly treated pediatric precursor B- ALL. Leukemia. 2010;24:1258–64. 28. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27:5202–7. 29. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80. 30. Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79 % of relapses in pediatric acute lymphoblastic leukemia. Leukemia; 2010. 31. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leuke- mia: a multicenter analysis in Taiwan. Cancer Sci. 2011;102:1874–81. 32. Venn NC, van der Velden VH, de Bie M, et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia; 2011. 33. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34. 34. Busslinger M. Transcriptional control of early B cell develop- ment. Annu Rev Immunol. 2004;22:55–79. 35. Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lym- phoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia; 2009. 36. Nebral K, Denk D, Attarbaschi A, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23:134–43. 37. Faderl S, Estrov Z, Kantarjian HM, et al. The incidence of chromo- some 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lympho- blastic leukemia. Cytokines Cell Mol Ther. 1999;5:159–63. 38. Heyman M, Rasool O, Borgonovo Brandter L, et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in child- hood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512–20. 39. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;469:362–7. 141 40. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid trans- formation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114:2688–98. 41. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome- associated acute lymphoblastic leukemia. Nat Genet. 2009; 41:1243–6. 42. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115:1006–17. 43. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107:252–7. 44. Liu YJ. TSLP in epithelial cell and dendritic cell cross talk. Adv Immunol. 2009;101:1–25. 45. Levin SD, Koelling RM, Friend SL, et al. Thymic stromal lym- phopoietin: a cytokine that promotes the development of IgM+B cells in vitro and signals via a novel mechanism. J Immunol. 1999;162:677–83. 46. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B- progenitor acute lymphoblastic leukemia. Blood. 2010;115:5312–21. 47. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115:5393–7. 48. Harrison CJ, Moorman AV, Barber KE, et al. Interphase molec- ular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukae- mia: a UK Cancer Cytogenetics Group Study. Br J Haematol. 2005;129:520–30. 49. Rand V, Parker H, Russell LJ, et al. Genomic characterization impli- cates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117:6848–55. 50. Moorman AV, Richards SM, Robinson HM, et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachro- mosomal amplification of chromosome 21 (iAMP21). Blood. 2007;109:2327–30. 51. Attarbaschi A, Mann G, Panzer-Grumayer R, et al. Minimal residual disease values discriminate between low and high re- lapse risk in children with B-cell precursor acute lymphoblas- tic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblas- tic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol. 2008;26:3046–50. 52. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL ki- nase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552–7. 53. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118:3080–7. 54. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235– 9. Mutations of CREBBP, occurring 8.3 % of relapse B-ALL, are either present at diagnosis or acquired at relapse, and resulted in truncated alleles or deleterious substitutions in conserved residues of the histone acetyltransferase domain that impair histone acety- lation and transcriptional regulation of CREBBP targets, including glucocorticoid responsive genes.